A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)

IRB/UVA Tracking #
20831
Contact
Maria Davenport
Contact Email
Contact Phone
1.434.297.4110
Phase
II
Primary purpose
Treatment
Cancer PI
Ryan Gentzler
Status
OPEN TO ACCRUAL
Ages
Adult